In Silico
Target Validation
Evaluate how a gene interacts within the molecular mechanisms that drive the cell, tissue functions and phenotypes associated with your disease of interest. Ask Euretos and do days if not weeks of online desk research in minutes. Available as platform subscription or consulting service.
TARGET VALIDATION EXAMPLE
ASK EURETOS
Evaluate all disease related molecular gene interactions
Leverage gene-disease annotations from over 200+ data sources in Euretos. Analyze all molecular interactions of the gene of interest but only where the interactors are disease related. For example differentially expression analysis provides only those genes that interact with the gene of interest and are differentially expressed for the disease
Evaluate target/biomarker suitability on 10 separate criteria
Evaluate 10 key aspects that are relevant to assess a gene as a viable target or biomarker for a disease including healthy expression, differential expression, gene variants, animal models, gene, protein & metabolite interactions, phenotypes, pathways, cell & molecular function and organ & tissue functions.
Latest News
Euretos AI Platform uncovers disease mechanism for novel melanoma target
Friday 07 September 2018In a recent study published in the Biomedicine & Pharmacotherapy journal, researchers identified TPX2 as a novel potential target for melanoma. The study found that TPX2 promotes the proliferation of melanoma cells and that inhibition of TPX2 d ...
Read More....Euretos AI Platform discovers key disease mechanisms for recently identified gastric cancer target.
Tuesday 21 August 2018In a recent study published in Nature Scientific Reports, researchers identified AEBP1 as a novel potential target for gastric cancer. The study found that both the mRNA and protein levels of AEBP1 were significantly increased in gastric cancer tis ...
Read More....Euretos invited to present on the use of AI in target & biomarker discovery at the annual Dutch Biotech Event
Wednesday 27 June 2018On friday the 29th of June, Euretos will be speaking at the annual Dutch Biotech Event on the use of the Euretos AI Platform in target & biomarker discovery. In the session Arie Baak will speak on the topic together with Peter de Keizer, one of ...
Read More....
Summary of Target Validation Capabilities
Healthy expression - Healthy RNA (fpkm) and protein expression (abundance) of the gene of interest from 5 expression sources including the identification of key associated tissues for the disease based on literature co-occurrence analysis.
Genetic annotations - Direct disease annotations for the gene of interest and all other disease annotated genes having molecular interaction with the gene of interest.
Differential Expression - Differential expression of the gene of interest and any other differentially expressed gene having molecular interaction with the gene of interest (with log2fold expression level).
Gene variants - Known disease causing mutations for the gene of interest and any other disease variant gene having molecular interaction with the gene of interest.
Animal models - Manipulated genes in animal models of the disease, and their molecular interactions with the gene of interest.
Metabolites - All disease associated metabolites that interact with the gene of interest and all disease associated metabolites that interact with genes having molecular interaction with the gene of interest.
Phenotypes - All phenotypes that are significantly associated with the entire set of genes that have molecular interaction with the gene of interest.
Pathways - All Pathways that are significantly associated with the entire set of genes that have molecular interaction with the gene of interest.
Cell or molecular functions - All cell and molecular functions that are significantly associated with the entire set of genes that have molecular interaction with the gene of interest.
Organ and tissue functions - All organ and tissue functions that are significantly associated with the entire set of genes that have molecular interaction with the gene of interest.